Therapeutic Potential of HNF4α in End-stage Liver Disease.

IF 1.6 4区生物学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Organogenesis Pub Date : 2021-10-02 DOI:10.1080/15476278.2021.1994273

Ricardo Diaz-Aragon, Michael C Coard, Sriram Amirneni, Lanuza Faccioli, Nils Haep, Michelle R Malizio, Takashi Motomura, Zehra N Kocas-Kilicarslan, Alina Ostrowska, Rodrigo M Florentino, Carla Frau

{"title":"Therapeutic Potential of HNF4α in End-stage Liver Disease.","authors":"Ricardo Diaz-Aragon, Michael C Coard, Sriram Amirneni, Lanuza Faccioli, Nils Haep, Michelle R Malizio, Takashi Motomura, Zehra N Kocas-Kilicarslan, Alina Ostrowska, Rodrigo M Florentino, Carla Frau","doi":"10.1080/15476278.2021.1994273","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of end-stage liver disease (ESLD) in the US is increasing at an alarming rate. It can be caused by several factors; however, one of the most common routes begins with nonalcoholic fatty liver disease (NAFLD). ESLD is diagnosed by the presence of irreversible damage to the liver. Currently, the only definitive treatment for ESLD is orthotopic liver transplantation (OLT). Nevertheless, OLT is limited due to a shortage of donor livers. Several promising alternative treatment options are under investigation. Researchers have focused on the effect of liver-enriched transcription factors (LETFs) on disease progression. Specifically, hepatocyte nuclear factor 4-alpha (HNF4α) has been reported to reset the liver transcription network and possibly play a role in the regression of fibrosis and cirrhosis. In this review, we describe the function of HNF4α, along with its regulation at various levels. In addition, we summarize the role of HNF4α in ESLD and its potential as a therapeutic target in the treatment of ESLD.</p>","PeriodicalId":19596,"journal":{"name":"Organogenesis","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2021-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208774/pdf/KOGG_17_1994273.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organogenesis","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/15476278.2021.1994273","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

The prevalence of end-stage liver disease (ESLD) in the US is increasing at an alarming rate. It can be caused by several factors; however, one of the most common routes begins with nonalcoholic fatty liver disease (NAFLD). ESLD is diagnosed by the presence of irreversible damage to the liver. Currently, the only definitive treatment for ESLD is orthotopic liver transplantation (OLT). Nevertheless, OLT is limited due to a shortage of donor livers. Several promising alternative treatment options are under investigation. Researchers have focused on the effect of liver-enriched transcription factors (LETFs) on disease progression. Specifically, hepatocyte nuclear factor 4-alpha (HNF4α) has been reported to reset the liver transcription network and possibly play a role in the regression of fibrosis and cirrhosis. In this review, we describe the function of HNF4α, along with its regulation at various levels. In addition, we summarize the role of HNF4α in ESLD and its potential as a therapeutic target in the treatment of ESLD.

Abstract Image

查看原文本刊更多论文

HNF4α在终末期肝病中的治疗潜力。

终末期肝病(ESLD)在美国的患病率正以惊人的速度增长。它可以由几个因素引起;然而，最常见的途径之一始于非酒精性脂肪性肝病(NAFLD)。ESLD是通过肝脏出现不可逆损伤来诊断的。目前，唯一确定的治疗ESLD是原位肝移植(OLT)。然而，由于供体肝脏的短缺，OLT是有限的。目前正在研究几种有希望的替代治疗方案。研究人员一直关注肝脏富集转录因子(LETFs)对疾病进展的影响。具体来说，有报道称肝细胞核因子4- α (HNF4α)可以重置肝脏转录网络，并可能在纤维化和肝硬化的消退中发挥作用。在这篇综述中，我们描述了HNF4α的功能，以及它在不同水平上的调控。此外，我们总结了HNF4α在ESLD中的作用及其作为治疗ESLD的治疗靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Organogenesis BIOCHEMISTRY & MOLECULAR BIOLOGY-DEVELOPMENTAL BIOLOGY

CiteScore

4.10

自引率

4.30%

发文量

审稿时长

>12 weeks

期刊介绍： Organogenesis is a peer-reviewed journal, available in print and online, that publishes significant advances on all aspects of organ development. The journal covers organogenesis in all multi-cellular organisms and also includes research into tissue engineering, artificial organs and organ substitutes. The overriding criteria for publication in Organogenesis are originality, scientific merit and general interest. The audience of the journal consists primarily of researchers and advanced students of anatomy, developmental biology and tissue engineering. The emphasis of the journal is on experimental papers (full-length and brief communications), but it will also publish reviews, hypotheses and commentaries. The Editors encourage the submission of addenda, which are essentially auto-commentaries on significant research recently published elsewhere with additional insights, new interpretations or speculations on a relevant topic. If you have interesting data or an original hypothesis about organ development or artificial organs, please send a pre-submission inquiry to the Editor-in-Chief. You will normally receive a reply within days. All manuscripts will be subjected to peer review, and accepted manuscripts will be posted to the electronic site of the journal immediately and will appear in print at the earliest opportunity thereafter.